Literature DB >> 34321660

Structural basis of ketamine action on human NMDA receptors.

Youyi Zhang1,2, Fei Ye3, Tongtong Zhang1,2, Shiyun Lv1,2, Liping Zhou2,4, Daohai Du4, He Lin5, Fei Guo4, Cheng Luo6,7, Shujia Zhu8,9,10.   

Abstract

Ketamine is a non-competitive channel blocker of N-methyl-D-aspartate (NMDA) receptors1. A single sub-anaesthetic dose of ketamine produces rapid (within hours) and long-lasting antidepressant effects in patients who are resistant to other antidepressants2,3. Ketamine is a racemic mixture of S- and R-ketamine enantiomers, with S-ketamine isomer being the more active antidepressant4. Here we describe the cryo-electron microscope structures of human GluN1-GluN2A and GluN1-GluN2B NMDA receptors in complex with S-ketamine, glycine and glutamate. Both electron density maps uncovered the binding pocket for S-ketamine in the central vestibule between the channel gate and selectivity filter. Molecular dynamics simulation showed that S-ketamine moves between two distinct locations within the binding pocket. Two amino acids-leucine 642 on GluN2A (homologous to leucine 643 on GluN2B) and asparagine 616 on GluN1-were identified as key residues that form hydrophobic and hydrogen-bond interactions with ketamine, and mutations at these residues reduced the potency of ketamine in blocking NMDA receptor channel activity. These findings show structurally how ketamine binds to and acts on human NMDA receptors, and pave the way for the future development of ketamine-based antidepressants.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2021        PMID: 34321660     DOI: 10.1038/s41586-021-03769-9

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  39 in total

Review 1.  Depression.

Authors:  Gin S Malhi; J John Mann
Journal:  Lancet       Date:  2018-11-02       Impact factor: 79.321

2.  Antidepressant effects of ketamine in depressed patients.

Authors:  R M Berman; A Cappiello; A Anand; D A Oren; G R Heninger; D S Charney; J H Krystal
Journal:  Biol Psychiatry       Date:  2000-02-15       Impact factor: 13.382

3.  Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval.

Authors:  Erick H Turner
Journal:  Lancet Psychiatry       Date:  2019-11-01       Impact factor: 27.083

4.  Ketamine blocks bursting in the lateral habenula to rapidly relieve depression.

Authors:  Yan Yang; Yihui Cui; Kangning Sang; Yiyan Dong; Zheyi Ni; Shuangshuang Ma; Hailan Hu
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

5.  Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).

Authors:  Maurizio Fava; Marlene P Freeman; Martina Flynn; Heidi Judge; Bettina B Hoeppner; Cristina Cusin; Dawn F Ionescu; Sanjay J Mathew; Lee C Chang; Dan V Iosifescu; James Murrough; Charles Debattista; Alan F Schatzberg; Madhukar H Trivedi; Manish K Jha; Gerard Sanacora; Samuel T Wilkinson; George I Papakostas
Journal:  Mol Psychiatry       Date:  2018-10-03       Impact factor: 15.992

6.  Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.

Authors:  Ronald S Duman; George K Aghajanian; Gerard Sanacora; John H Krystal
Journal:  Nat Med       Date:  2016-03       Impact factor: 53.440

7.  Medication augmentation after the failure of SSRIs for depression.

Authors:  Madhukar H Trivedi; Maurizio Fava; Stephen R Wisniewski; Michael E Thase; Frederick Quitkin; Diane Warden; Louise Ritz; Andrew A Nierenberg; Barry D Lebowitz; Melanie M Biggs; James F Luther; Kathy Shores-Wilson; A John Rush
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

Review 8.  The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.

Authors:  Samuel T Wilkinson; Elizabeth D Ballard; Michael H Bloch; Sanjay J Mathew; James W Murrough; Adriana Feder; Peter Sos; Gang Wang; Carlos A Zarate; Gerard Sanacora
Journal:  Am J Psychiatry       Date:  2017-10-03       Impact factor: 18.112

9.  NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.

Authors:  Anita E Autry; Megumi Adachi; Elena Nosyreva; Elisa S Na; Maarten F Los; Peng-fei Cheng; Ege T Kavalali; Lisa M Monteggia
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

10.  Ketamine: A tale of two enantiomers.

Authors:  Luke A Jelen; Allan H Young; James M Stone
Journal:  J Psychopharmacol       Date:  2020-11-06       Impact factor: 4.153

View more
  10 in total

Review 1.  Mechanisms of ketamine and its metabolites as antidepressants.

Authors:  Evan M Hess; Lace M Riggs; Michael Michaelides; Todd D Gould
Journal:  Biochem Pharmacol       Date:  2021-12-27       Impact factor: 5.858

2.  A Breakthrough in Understanding the Rapid Antidepressant Effect of Ketamine Based on Structural Analysis.

Authors:  Hongmei Liu; Xiaohui Wu; Jun Chen; Yiru Fang
Journal:  Neurosci Bull       Date:  2021-11-16       Impact factor: 5.203

3.  N-Methyl-d-aspartic Acid (NMDA) Receptor Is Involved in the Inhibitory Effect of Ketamine on Human Sperm Functions.

Authors:  Ying Chen; Wenqing Xu; Yuan Yuan; Houyang Chen; Shuangyan Zheng; Yuanqiao He; Tao Luo
Journal:  Int J Mol Sci       Date:  2021-11-16       Impact factor: 5.923

4.  Inflammation and serotonin deficiency in major depressive disorder: molecular docking of antidepressant and anti-inflammatory drugs to tryptophan and indoleamine 2,3-dioxygenases.

Authors:  Shazia Dawood; Samina Bano; Abdulla A-B Badawy
Journal:  Biosci Rep       Date:  2022-05-27       Impact factor: 3.976

Review 5.  Uncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant.

Authors:  Songbai Xu; Xiaoxiao Yao; Bingjin Li; Ranji Cui; Cuilin Zhu; Yao Wang; Wei Yang
Journal:  Front Pharmacol       Date:  2022-07-07       Impact factor: 5.988

Review 6.  The molecular pathophysiology of depression and the new therapeutics.

Authors:  Haihua Tian; Zhenyu Hu; Jia Xu; Chuang Wang
Journal:  MedComm (2020)       Date:  2022-07-21

Review 7.  Protein quality control of N-methyl-D-aspartate receptors.

Authors:  Taylor M Benske; Ting-Wei Mu; Ya-Juan Wang
Journal:  Front Cell Neurosci       Date:  2022-07-22       Impact factor: 6.147

Review 8.  Simulation and Machine Learning Methods for Ion-Channel Structure Determination, Mechanistic Studies and Drug Design.

Authors:  Zhengdan Zhu; Zhenfeng Deng; Qinrui Wang; Yuhang Wang; Duo Zhang; Ruihan Xu; Lvjun Guo; Han Wen
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

9.  Cannabidiol prevents methamphetamine-induced neurotoxicity by modulating dopamine receptor D1-mediated calcium-dependent phosphorylation of methyl-CpG-binding protein 2.

Authors:  Baoyu Shen; Ruilin Zhang; Genmeng Yang; Yanxia Peng; Qianyun Nie; Hao Yu; Wenjuan Dong; Bingzheng Chen; Chunhui Song; Yan Tian; Lixiang Qin; Junjie Shu; Shijun Hong; Lihua Li
Journal:  Front Pharmacol       Date:  2022-09-06       Impact factor: 5.988

10.  Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors.

Authors:  Ezio Bettini; Stephen M Stahl; Sara De Martin; Andrea Mattarei; Jacopo Sgrignani; Corrado Carignani; Selena Nola; Patrizia Locatelli; Marco Pappagallo; Charles E Inturrisi; Francesco Bifari; Andrea Cavalli; Andrea Alimonti; Luca Pani; Maurizio Fava; Sergio Traversa; Franco Folli; Paolo L Manfredi
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.